GLPG3970 ( DrugBank: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2
53	シェーグレン症候群	6
97	潰瘍性大腸炎	2

46. 悪性関節リウマチ

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000658-83-BG (EUCTR)	21/10/2020	07/10/2020	A study evaluating the effects of GLPG3970 given as an oral treatment for 6 weeks in adults with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate	Rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	25	Phase 2	Poland;Ukraine;Georgia;Bulgaria
2	NCT04577781 (ClinicalTrials.gov)	October 12, 2020	30/9/2020	A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: GLPG3970;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	64 Years	All	28	Phase 2	Bulgaria;Georgia;Poland;Ukraine

53. シェーグレン症候群

臨床試験数 : 283 / 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-003298-22-ES (EUCTR)	06/07/2021	09/02/2021	A study evaluating the effects of GLPG3970 given as an oral treatment for 12 weeks in adults with active primary Sjögren’s Syndrome	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks in adult subjects with active primary Sjögren’s Syndrome	Primary Sjogren's Syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	France;Hungary;Greece;Poland;Spain;Ukraine;Netherlands;Germany;United Kingdom
2	EUCTR2020-003298-22-DE (EUCTR)	26/02/2021	26/11/2020	A study evaluating the effects of GLPG3970 given as an oral treatment for 12 weeks in adults with active primary Sjögren’s Syndrome	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks in adult subjects with active primary Sjögren’s Syndrome	Primary Sjogren's Syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	France;Hungary;Greece;Spain;Poland;Ukraine;Germany;United Kingdom
3	EUCTR2020-003298-22-HU (EUCTR)	10/02/2021	30/11/2020	A study evaluating the effects of GLPG3970 given as an oral treatment for 12 weeks in adults with active primary Sjögren’s Syndrome	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks in adult subjects with active primary Sjögren’s Syndrome	Primary Sjogren's Syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	Poland;Ukraine;Netherlands;Germany;United Kingdom;France;Hungary;Greece;Spain
4	EUCTR2020-003298-22-GR (EUCTR)	02/02/2021	13/12/2020	A study evaluating the effects of GLPG3970 given as an oral treatment for 12 weeks in adults with active primary Sjögren’s Syndrome	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks in adult subjects with active primary Sjögren’s Syndrome	Primary Sjogren's Syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	France;Hungary;Greece;Spain;Poland;Ukraine;Netherlands;Germany;United Kingdom
5	NCT04700280 (ClinicalTrials.gov)	January 28, 2021	6/1/2021	A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Primary Sjögren's Syndrome	Primary Sjögren Syndrome	Drug: GLPG3970;Drug: Placebo	Galapagos NV	NULL	Active, not recruiting	18 Years	74 Years	All	31	Phase 2	France;Germany;Greece;Hungary;Poland;Spain;Ukraine
6	EUCTR2020-003298-22-FR (EUCTR)	15/01/2021	19/11/2020	A study evaluating the effects of GLPG3970 given as an oral treatment for 12 weeks in adults with active primary Sjögren’s Syndrome	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks in adult subjects with active primary Sjögren’s Syndrome	Primary Sjogren's Syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	France;Hungary;Greece;Spain;Poland;Ukraine;Netherlands;Germany;United Kingdom

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04577794 (ClinicalTrials.gov)	October 5, 2020	30/9/2020	A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis	Ulcerative Colitis	Drug: GLPG3970;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	64 Years	All	31	Phase 2	Georgia;Moldova, Republic of;Poland;Ukraine
2	EUCTR2020-000659-11-PL (EUCTR)	10/09/2020	23/07/2020	A study evaluating the effects of GLPG3970 given as an oral treatment for 6 weeks in adults with ulcerative colitis	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects with moderately to severely active ulcerative colitis	Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive name: GLPG3970	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	Poland;Ukraine;Georgia;Moldova, Republic of

先頭へ